Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML.
| Image |  |
|---|---|
| Description | scientific article published on 20 March 2013 |
| Author/s |
author: Nancy Briggs David Ross |
| Publication date | March 20, 2013 |
| Language | English |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |